How many clinical-trial readouts are scheduled for April 2027?

pdufa.bio currently tracks 27 clinical-trial readouts with dates in April 2027, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › Readouts › April 2027

April 2027 clinical-trial readouts

trial-readout estimates for April 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← March 2027 May 2027 →

27 readouts

IXHL · Apr 2027 (est.)

IHL-42X Low Dose — Obstructive Sleep Apnea (OSA)

CGTX · Apr 2027 (est.)

Dextromethorphan-Bupropion — Early Alzheimer's Disease

CLYM · Apr 2027 (est.)

Budoprutug — Systemic Lupus Erythematosus

GKOS · Apr 2027 (est.)

GLK-221 — Keratoconus

KOD · Apr 2027 (est.)

KSI-101 — Macular Edema Secondary to Inflammation

KPTI · Apr 2027 (est.)

Selinexor — Multiple Myeloma

KYTX · Apr 2027 (est.)

Standard of Care Treatment — Multiple Sclerosis, Primary Progressive

LONA · Apr 2027 (est.)

Lasofoxifene in combination with abemaciclib — Metastatic Breast Cancer

MNOV · Apr 2027 (est.)

MN-166 — Amyotrophic Lateral Sclerosis

PBLS · Apr 2027 (est.)

FOG-001 — Cancer

NKTX · Apr 2027 (est.)

NKX019 — Lupus Nephritis

SMMT · Apr 2027 (est.)

Ivonescimab — Endometrial Cancer

TLSA · Apr 2027 (est.)

Foralumab Nasal — Multiple System Atrophy

VSTM · Apr 2027 (est.)

avutometinib — Low-Grade Serous Ovarian Cancer

VTVT · Apr 2027 (est.)

Cadisegliatin — Type 1 Diabetes (T1D)

XENE · Apr 2027 (est.)

Azetukalner — Primary Generalized Tonic-Clonic Seizures

CLDX · Apr 2027 (est.)

Barzolvolimab — Malignant Epithelial Neoplasms

TLX · Apr 2027 (est.)

177Lu-TLX591 — Bone Pain

ALNY · Apr 2027 (est.)

ALN-2232 — Obesity

IOVA · Apr 2027 (est.)

Lifileucel plus Pembrolizumab — Bone Sarcoma

IDYA · Apr 2027 (est.)

Darovasertib — Uveal Melanoma

ISRG · Apr 2027 (est.)

filricianine — Ureter Injury

NBTX · Apr 2027 (est.)

NBTXR3 — Radiotherapy

NVS · Apr 2027 (est.)

Iptacopan — Generalized Myasthenia Gravis

REGN · Apr 2027 (est.)

Cemiplimab — Colon Cancer

RLAY · Apr 2027 (est.)

RLY-2608 — PIK3CA Mutation

AIM · Apr 2027 (est.)

Ampligen — Prostate Adenocarcinoma

Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).